[Advisability of using probiotics in the treatment of atherogenic dyslipidemia]

One of the main components of the metabolic syndrome is a non-alcoholic fatty liver disease (NAFLD). Currently, NAFLD is recognized as one of the main factors for cardiovascular disease because cholesterol synthesis is carried out mainly in the liver. In connection with this selection of lipid-lowering therapy, which has a known hepatotoxic effect, is a challenge. In the pathogenesis of NAFLD important role played by the violation of the colon microflora and, consequently, elevated levels of metabolic products of microorganisms (short chain fatty acids, endotoxin, nitric oxide), which must also be considered in the treatment of atherogenic dyslipidemia. In patients with NAFLD and atherogenic dyslipidemia appointment of combination therapy of statins and probiotics are more effective in lowering cholesterol and products of metabolism of intestinal microflora compared with monotherapy.